List view / Grid view
14 July 2021 | By Analytik Jena
In this on-demand webinar, based on field experiences with our research partners, Analytik Jena provides an overview of application demands for a reliable sample preparation automation – from a small and easy-to-use workstation, to a fully automated integration solution by Analytik Jena.
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
US researchers have developed an antisperm monoclonal antibody that could become a safe and effective birth control method.
Researchers in Australia have discovered a new site on the COVID-19 Spike protein that could be targeted by an anticoagulant drug.
A metabolic control pathway that regulates T follicular helper cells could enhance vaccine effectiveness, including those that protect against COVID-19.
10 reasons to choose Bethyl antibodies and reagents from Fortis Life Sciences for your applications.
As interest in biotherapeutic proteins grows, the need to reduce cell line development costs and the time to market is more critical than ever.
Learn quick technical tips to optimise your ELISA workflow, including how to: select the right ELISA kit, avoid contamination and normalise data.
Researchers have designed an antibody that attaches to MuSK, which prevented early lethality of mice with congenital myasthenia.
Researchers have used a new method for discovering nanobodies to identify potential therapeutics against SARS-CoV-2 infection.
Discover the new Octet R series systems, a comprehensive solution for screening and characterising molecular interactions such as protein-protein or protein-drug interactions.
Sino Biological is an international reagent supplier and service provider. The company specialises in recombinant protein production and antibody development.
Solutions to help you understand viral diseases and translate your research findings into better treatments and vaccines.
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
The binding specificity and high binding affinity of therapeutic antibodies makes them an ideal therapy for treating a wide range of human disorders. Advancements in antibody technologies have resulted in huge development success along with a boost in novel and improved treatment strategies. However, specific challenges and considerations are faced…
